Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • HM43239 for AML
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • HM43239 for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017

Apr 24, 2017 8:30am EDT

Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting

Apr 19, 2017 8:30am EDT

Aptose Reports Fourth Quarter and Year End 2016 Results

Mar 28, 2017 5:03pm EDT

Aptose Announces Planned Departure of Chief Business Officer

Mar 27, 2017 8:00am EDT

Aptose to Participate in Upcoming Investor Conferences

Mar 02, 2017 7:00am EST

Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day

Feb 02, 2017 7:00am EST

Aptose Prioritizes Development of CG’806 First-in Class FLT3/BTK Inhibitor

Jan 23, 2017 7:00am EST

Aptose Biosciences to Present at Biotech Showcase 2017 Conference

Jan 05, 2017 8:00am EST

Aptose Biosciences Provides Update on APTO-253 Development

Dec 29, 2016 8:00am EST

Aptose Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2016

Nov 14, 2016 7:22pm EST
RSS
  • Prev
    • 1...
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • ...24
    Next
    © 2022 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap